India's Syngene International slides to 6-year low on Q1 loss, full-year forecast

Syngene International

30/07/2026 05:41

** India's Syngene International SYNN.NS slides 9.4% to six-year low of 375.25 rupees
** Pharmaceutical contract research firm posts 90 million rupees ($941,422.59) loss for Q1, vs profit of 867 million rupees a year ago
** Revenue drops 15.8% year-on-year; co says performance impacted by lower offtake from a major client and forex hedge losses
** Co expects fiscal year 2027 revenue to drop in single-digit in rupee terms and operating margins in mid-20s
** Brokerage ICICI Securities says Q1 performance was below par across all parameters
** Adds that while recent contract extension with global biopharma company Bristol Myers Squibb BMY.N till 2035 is a positive development, poor earnings and prolonged recovery would be a major dampener for investors
** More than 4.1 million shares change hands, ~5x of 30-day average daily volume
** Stock rated "Buy" on average by eight brokerage firms, median PT at 532 rupees, per data compiled by LSEG
** YTD, SYNN down 40%



($1 = 95.6000 Indian rupees)

 (Reporting by Vivek Kumar M)
 ((VivekKumar.M@thomsonreuters.com;))